Has Wayne Solley, MD received payments from drug or device companies?

Yes. Drug and device makers reported $20,097 in general payments to Wayne Solley, MD across 99 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Wayne Solley, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Wayne Solley, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Wayne Solley, MD

Ophthalmology · Arlington, TXNPI 1528042447

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,363 of the $20,097 with a category attached, or 61.5%. Amgen accounts for 70.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $12,721 and has fallen 83.7% since, to $2,074 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,097in general payments, 2019–2025

Across 99 payments — averaging $203.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$14K
Ocular Therapeutix, Inc.$2K
Carl Zeiss Meditec, Inc.$1K
Genentech USA, Inc.$498
Apellis Pharmaceuticals, Inc.$481
Regeneron Healthcare Solutions, Inc.$393
plus $1K from 10 others

$1,434,915in research payments, 2019–2025

Across 111 payments — averaging $12,927 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Roche TCRC, Inc.$706K
Genentech, Inc.$500K
Ocular Therapeutix, Inc.$151K
Hexal AG$43K
AbbVie$35K

What the payments were for

Consulting fees$12,36362%
Travel & lodging$3,33317%
Food & beverage$2,92815%
Education$150%
Gifts$1,4597%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	30	$14,073
Ocular Therapeutix, Inc.	4	$2,164
Carl Zeiss Meditec, Inc.	1	$1,459
Genentech USA, Inc.	16	$498
Apellis Pharmaceuticals, Inc.	8	$481
Regeneron Healthcare Solutions, Inc.	10	$393
AbbVie(2 entities)	9	$203
Coherus Oncology, Inc.	6	$179
Astellas Pharma US Inc	3	$166
Novartis	2	$161
Alimera Sciences, Inc.	2	$153
Harrow Eye, LLC	2	$50
Eyepoint US, Inc.	2	$47
Halozyme Inc	2	$31
Sandoz	1	$25
Bausch & Lomb Americas Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PAVBLU$10,363
CLARUS$1,459
Syfovre$371
BEOVU$143
YUTIQ$130
EYLEA HD$122
Izervay$109
SUSVIMO$105

How this compares

$20,097 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas →

Medicare billing

Part B allowed, 2024

$5,867,703

Medicare patients

1,177

Services billed

52,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	262	$7,662
MoxifloxacinMoxifloxacin Hcl	203	$5,113
Bromfenac Sodium	16	$2,902
Tobramycin-DexamethasoneTobramycin/Dexamethasone	59	$2,763
Brimonidine Tartrate	26	$2,595
Difluprednate	24	$2,360
Loteprednol Etabonate	11	$1,079
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	89	$972
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	61	$694
Ketorolac Tromethamine	15	$324
Latanoprost	29	$191
Tramadol Hcl	79	$125

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Arlington

Aaleya KoreishiArlington$144K
Michael SingerSan Antonio$1.8M
Oluwatosin SmithDallas$1.5M
Charles WykoffBellaire$1.5M
John MichelettiHouston$916K
Davinder GroverDallas$705K
Christina WengHouston$676K
Peter ChangHouston$656K
Zaina Al-MohtasebHouston$636K
Ashkan AbbeyDallas$559K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →